mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kwon Jennie H, Tenforde Mark W, Gaglani Manjusha, Talbot H Keipp, Ginde Adit A, McNeal Tresa, Ghamande Shekhar, Douin David J, Casey Jonathan D, Mohr Nicholas M, Zepeski Anne, Shapiro Nathan I, Gibbs Kevin W, Files D Clark, Hager David N, Shehu Arber, Prekker Matthew E, Caspers Sean D, Exline Matthew C, Botros Mena, Gong Michelle N, Li Alex, Mohamed Amira, Johnson Nicholas J, Srinivasan Vasisht, Steingrub Jay S, Peltan Ithan D, Brown Samuel M, Martin Emily T, Khan Akram, Hough Catherine L, Busse Laurence W, Duggal Abhijit, Wilson Jennifer G, Perez Cynthia, Chang Steven Y, Mallow Christopher, Rovinski Randal, Babcock Hilary M, Lauring Adam S, Felley Laura, Halasa Natasha, Chappell James D, Grijalva Carlos G, Rice Todd W, Womack Kelsey N, Lindsell Christopher J, Hart Kimberly W, Baughman Adrienne, Olson Samantha M, Schrag Stephanie, Kobayashi Miwako, Verani Jennifer R, Patel Manish M, Self Wesley H
Аннотация
METHODS: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls.
RESULTS: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses.
CONCLUSIONS: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.